shutterstock_1492661771_ricochet64
ricochet64 / Shutterstock.com
8 December 2020AmericasMuireann Bolger

Neurim prevails against Mylan in suit over insomnia drug

Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the  English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Big Pharma
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Big Pharma
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Big Pharma
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Big Pharma
25 March 2019   The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
Big Pharma
26 June 2020   The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Big Pharma
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.